KLK3 and pachyonychia congenita: Prostate-specific antigen (PSA) represents a reliable and useful biomarker for early detection and early diagnosis of disease progression and it has been reported that PSA screening has a potential benefit of decreasing deaths from PC in men aged 55 to 69 years old [5].